Eli Lilly in Talks to Buy Kelonia for Over $2 Billion

ELI LILLY & CO is reportedly in advanced negotiations to acquire Kelonia Therapeutics for a sum exceeding $2 billion, according to a report from the Wall Street Journal on Sunday. The potential acquisition marks a significant move for the pharmaceutical giant as it continues to expand its presence in the biotechnology sector and bolster its research pipeline.